(NASDAQ: SEPN) Septerna's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 126.68%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.86%.
Septerna's revenue in 2025 is N/A.On average, 1 Wall Street analysts forecast SEPN's revenue for 2025 to be $3,262,561,508, with the lowest SEPN revenue forecast at $3,262,561,508, and the highest SEPN revenue forecast at $3,262,561,508. On average, 1 Wall Street analysts forecast SEPN's revenue for 2026 to be $4,233,042,110, with the lowest SEPN revenue forecast at $4,233,042,110, and the highest SEPN revenue forecast at $4,233,042,110.
In 2027, SEPN is forecast to generate $2,227,916,900 in revenue, with the lowest revenue forecast at $2,227,916,900 and the highest revenue forecast at $2,227,916,900.